Results 71 to 80 of about 1,741 (166)

Management of Uncontrolled Asthma: A Framework for Novel and Legacy Biologic Treatments

Journal of Asthma and Allergy, 2022
Laren D Tan,1,2 Nolan Nguyen,3 Abdullah Alismail,2 Mario Castro4 1Department of Internal Medicine, School of Medicine, Loma Linda University Health, Loma Linda, CA, USA; 2Department of Cardiopulmonary Sciences, School of Allied Health Professions, Loma ...
Tan LD, Nguyen N, Alismail A, Castro M
doaj  

Tezepelumab-ekko

American Journal of Health-System Pharmacy, 2022
openaire   +2 more sources

Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials

COPD
Background Despite limited breakthroughs in COPD pharmacotherapy, recent trials have shown promising results for biologics in COPD patients. However, robust evidence synthesis in this area is currently lacking.Methods We conducted a systematic review of ...
Tyler Pitre, Daniel Lupas, Jasmine Mah, Matthew Stanbrook, Alina Blazer, Dena Zeraatkar, Terence Ho   +6 more
doaj   +1 more source

Efficacy of tezepelumab against uncontrolled severe non‐type 2 asthma refractory to bronchial thermoplasty, benralizumab, dupilumab and mepolizumab

Respirology Case Reports
Severe asthma affects approximately 5%–10% of patients with asthma. Herein, we describe a case of non‐type 2 asthma that progressively worsened over the years. An 80‐year‐old woman was diagnosed with asthma 11 years back.
Yoshiro Kai, Kentaro Suzuki, Ryosuke Kataoka, Ichiro Sato, Shinji Tamaki, Shigeo Muro   +5 more
doaj   +1 more source

Tezepelumab: patient selection and place in therapy in severe asthma

Journal of International Medical Research
Asthma is a disease characterised by heterogeneous and multifaceted airway inflammation. Despite the availability of effective treatments, a substantial percentage of patients with the type 2 (T2)-high, but mainly the T2-low, phenotype complain of persistent symptoms, airflow limitation, and poor response to treatments.
Francesco Menzella, Sara Munari, Lorenzo Corsi, Silvia Tonin, Walter Cestaro, Andrea Ballarin, Ariel Floriani, Cristina Dartora, Gianenrico Senna   +8 more
openaire   +3 more sources

Tezepelumab attenuates exertional symptom burden in severe asthma: insights from a real-world cohort

Frontiers in Allergy
BackgroundExertional symptom burden is an important yet insufficiently characterised component of morbidity in severe asthma. Tezepelumab, a monoclonal antibody targeting thymic stromal lymphopoietin (TSLP), reduces exacerbations and improves asthma ...
Slagjana Stoshikj, Slagjana Stoshikj, Katharina Marth, Daniela Boryshchuk, Robin Ristl, Andreas Renner, Andreas Renner, Christina Bal, Christina Bal, Karin Patocka, Wolfgang Pohl, Karin Vonbank, Karin Vonbank, Marco Idzko, Marco Idzko   +14 more
doaj   +1 more source

Tezepelumab for Severe Asthma: One Drug Targeting Multiple Disease Pathways and Patient Types

Journal of Asthma and Allergy
Reynold Panettieri Jr,1 Njira Lugogo,2 Jonathan Corren,3 Christopher S Ambrose4 1Rutgers Institute for Translational Medicine and Science, Rutgers University, New Brunswick, NJ, USA; 2Michigan Medicine Asthma Program, University of Michigan, Ann Arbor ...
Panettieri R Jr, Lugogo N, Corren J, Ambrose CS   +3 more
doaj  

TSLP‐targeting therapy: Beyond allergy?

Clinical and Translational Medicine, 2023
Risa Ebina‐Shibuya, Warren J. Leonard
doaj   +1 more source

Is Tezepelumab effective in treatment of chronic rhinosinusitis with nasal Polyps?

The Egyptian Journal of Otolaryngology
Background Chronic rhinosinusitis (CRS) is a highly prevalent inflammatory condition of the paranasal sinuses and nasal cavities, which affects 5% to 28% of the general population and can have a profound impact on quality of life.
Mohamed M. Thabit, Hesham A. El-Sersy, Tarek A. Hamdy, Mohammed Aleem   +3 more
doaj   +1 more source

Cycling biologic therapy with tezepelumab and mepolizumab for eosinophilic otitis media and eosinophilic pneumonia in a patient with asthma. [PDF]

J Allergy Clin Immunol Glob
Matsuno O, Kawashima K, Hanada Y, Wibowo T, Ishida Y, Ogata A.   +5 more
europepmc   +1 more source